Cyclerion Therapeutics IncNASDAQ:CYCNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE4.3500
- TODAY'S CHANGE (%)0.0100 (0.2304%)
- Bid / Lots4.3500/ 1
- Ask / Lots4.4100/ 3
- Open / Previous Close4.4100 / 4.3400
- Day Range
- 52 Week Range
- Volume12,442
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CYCN |
|---|---|---|
| 11:00 ET | 1300 | 4.37 |
| 11:02 ET | 400 | 4.35 |
| 11:04 ET | 755 | 4.37 |
| 11:06 ET | 1937 | 4.42 |
| 11:11 ET | 1000 | 4.45 |
| 11:13 ET | 1870 | 4.56 |
| 11:15 ET | 900 | 4.52 |
| 11:18 ET | 200 | 4.46 |
| 11:22 ET | 200 | 4.5 |
| 03:34 ET | 1440 | 4.35 |
May 15, 2023
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split, from 5:03PM ET on Monday May 15, 2023 by MT Newswires
5:03PM ET on Monday May 15, 2023 by MT NewswiresBRIEF-Cyclerion Announces Reverse Stock Split, from 1:17PM ET on Monday May 15, 2023 by Thomson Reuters
1:17PM ET on Monday May 15, 2023 by Thomson ReutersCyclerion Announces Reverse Stock Split, from 1:00PM ET on Monday May 15, 2023 by GlobeNewswire
1:00PM ET on Monday May 15, 2023 by GlobeNewswire
May 12, 2023
Cyclerion Therapeutics to Sell Zagociguat, CY3018 Assets to New Private Company, from 4:48AM ET on Friday May 12, 2023 by MT Newswires
4:48AM ET on Friday May 12, 2023 by MT Newswires
May 11, 2023
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results, from 6:00PM ET on Thursday May 11, 2023 by GlobeNewswire
6:00PM ET on Thursday May 11, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cyclerion Therapeutics Inc | 9.4M | -5.0x | --- |
AcelRx Pharmaceuticals Inc | 10.7M | 0.2x | --- |
Bellicum Pharmaceuticals Inc | 7.3M | -0.8x | --- |
Aeglea Bio Therapeutics Inc | 8.4M | -0.2x | --- |
Catalyst Biosciences Inc | 8.7M | 1.0x | --- |
Theralink Technologies Inc | 9.8M | -0.2x | --- |
Company Information
Cyclerion Therapeutics, Inc. is a biopharmaceutical company. Its portfolio includes novel soluble guanylate cyclase (sGC) stimulators that modulate a key node in a fundamental signaling network in both the central nervous system (CNS) and the periphery. Zagociguat is a clinical-stage CNS-penetrant sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY 3018 is a CNS-targeted sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. and being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases.
Contact Information
- Headquarters
- 155 Federal Street, Suite 700BOSTON, MA, United States 02110-1727
- Phone
- 617-621-7722
- Fax
- ---
Executives
- Independent Chairman of the Board
- Marsha Fanucci
- Chief Executive Officer, Director
- Peter Hecht
- Chief Financial Officer, Corporate Secretary
- Anjeza Gjino
- Chief Operating Officer
- Cheryl Gault
- Independent Director
- George Conrades
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.4M |
|---|---|
Revenue (TTM) | $914.0K |
Shares Outstanding | 2.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.93 |
EPS | $-0.88 |
Book Value | $0.24 |
P/E Ratio | -5.0x |
Price/Sales (TTM) | 10.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,204.60% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
